NEJM This Week — July 30, 2026
Summary
This episode highlights advances in treating prostate cancer, multiple myeloma, acute pain, and IgA nephropathy, alongside a review of platelet factor 4 disorders and a case of mucosal leishmaniasis. Perspectives explore the paradox of medical aid in dying, federal authority over health care standards, litigation against tech companies, and the challenges of breaking bad news to patients.
Topics discussed
Introduction and episode overview
PARP inhibitor trial in metastatic prostate cancer
Ticilizumab for relapsed multiple myeloma
NAV 1.8 inhibitor for acute postoperative pain
Iptecopan for IgA nephropathy
Platelet factor 4 disorders and HIT/VITT
Case of persistent nasal ulceration
The paradox of medical aid in dying
Federal authority over medical standards
Litigation against health-risk products
Breaking bad news to patients
Images in clinical medicine and closing
Listen ad-free on Castria